Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 40

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Oct 28, 2006; 12(40): 6522-6526
Published online Oct 28, 2006. doi: 10.3748/wjg.v12.i40.6522

Table 2 Response to therapy n (%)

CR: Complete remission; PR: Partial response; NC: No change; PD: Progressive disease; RR: Response rate.

Citation: Imamura H, Ikeda M, Furukawa H, Tsujinaka T, Fujitani K, Kobayashi K, Narahara H, Kato M, Imamoto H, Takabayashi A, Tsukuma H. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol 2006; 12(40): 6522-6526
URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6522.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i40.6522

Imamura H, Ikeda M, Furukawa H, Tsujinaka T, Fujitani K, Kobayashi K, Narahara H, Kato M, Imamoto H, Takabayashi A, Tsukuma H. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol 2006; 12(40): 6522-6526 [PMID: 17072984 DOI: 10.3748/wjg.v12.i40.6522]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.